RxDoctor Payments Data

Sara Adkison

Physician Assistant · Scotts Valley, CANPI 1780280594

Payments from drug & device makers

$3,722in general payments, 2019–2025

Across 177 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$867
  • Novo Nordisk$723
  • Amgen$452
  • Pfizer$312
  • Lilly USA, LLC$280
  • GSK$174
  • plus $912 from 14 others

What the payments were for

  • Food & beverage$3,722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,722 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$5,761
Medicare patients
41
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$32,738
SynjardyEmpagliflozin/Metformin Hcl29$26,951
Repatha SureclickEvolocumab35$23,043
JardianceEmpagliflozin19$20,301
KerendiaFinerenone12$17,636
LinzessLinaclotide12$5,894
Atorvastatin Calcium63$628
Losartan Potassium59$361
Fluticasone Propionate24$320
Rosuvastatin Calcium29$284
Metformin Hcl28$279
Gabapentin19$225
Alendronate Sodium24$164
Escitalopram Oxalate16$124
Lisinopril17$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSynjardy, Jardiance$123$47,25248 claims
Lilly USA, LLCMounjaro$280$32,73829 claims
BayerKerendia$133$17,63612 claims
AbbVieLinzess$867$5,89412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Scotts Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →